Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. more
Time Frame | MRNA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.61% | -3.35% | -2.97% |
1-Month Return | 6.09% | -3.49% | -0.66% |
3-Month Return | -41.84% | -12.6% | 2.71% |
6-Month Return | -70.57% | -6.91% | 7.21% |
1-Year Return | -55.6% | 1.19% | 23.04% |
3-Year Return | -85.69% | -0.21% | 28.43% |
5-Year Return | 103.81% | 33.09% | 82.88% |
10-Year Return | 112.69% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 48.04M | 274.49M | 17.74B | 19.26B | 6.85B | [{"date":"2019-12-31","value":0.25,"profit":true},{"date":"2020-12-31","value":1.42,"profit":true},{"date":"2021-12-31","value":92.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":35.55,"profit":true}] |
Cost of Revenue | 496.31M | 7.93M | 2.62B | 5.42B | 4.69B | [{"date":"2019-12-31","value":9.16,"profit":true},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":48.32,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.65,"profit":true}] |
Gross Profit | 48.04M | 266.56M | 15.12B | 13.85B | 2.15B | [{"date":"2019-12-31","value":0.32,"profit":true},{"date":"2020-12-31","value":1.76,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.59,"profit":true},{"date":"2023-12-31","value":14.25,"profit":true}] |
Gross Margin | 100.00% | 97.11% | 85.24% | 71.88% | 31.47% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":97.11,"profit":true},{"date":"2021-12-31","value":85.24,"profit":true},{"date":"2022-12-31","value":71.88,"profit":true},{"date":"2023-12-31","value":31.47,"profit":true}] |
Operating Expenses | 593.76M | 1.03B | 1.82B | 4.43B | 6.39B | [{"date":"2019-12-31","value":9.29,"profit":true},{"date":"2020-12-31","value":16.1,"profit":true},{"date":"2021-12-31","value":28.51,"profit":true},{"date":"2022-12-31","value":69.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (545.72M) | (763.14M) | 13.30B | 9.42B | (4.24B) | [{"date":"2019-12-31","value":-4.1,"profit":false},{"date":"2020-12-31","value":-5.74,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.85,"profit":true},{"date":"2023-12-31","value":-31.88,"profit":false}] |
Total Non-Operating Income/Expense | 62.92M | 33.46M | 7.00M | 355.00M | 660.00M | [{"date":"2019-12-31","value":9.53,"profit":true},{"date":"2020-12-31","value":5.07,"profit":true},{"date":"2021-12-31","value":1.06,"profit":true},{"date":"2022-12-31","value":53.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (514.72M) | (744.51M) | 13.29B | 9.57B | (3.94B) | [{"date":"2019-12-31","value":-3.87,"profit":false},{"date":"2020-12-31","value":-5.6,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.07,"profit":true},{"date":"2023-12-31","value":-29.67,"profit":false}] |
Income Taxes | (695.00K) | 2.55M | 1.08B | 1.21B | 772.00M | [{"date":"2019-12-31","value":-0.06,"profit":false},{"date":"2020-12-31","value":0.21,"profit":true},{"date":"2021-12-31","value":89.28,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":63.64,"profit":true}] |
Income After Taxes | (514.02M) | (747.06M) | 12.20B | 8.36B | (4.71B) | [{"date":"2019-12-31","value":-4.21,"profit":false},{"date":"2020-12-31","value":-6.12,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":68.53,"profit":true},{"date":"2023-12-31","value":-38.63,"profit":false}] |
Income From Continuous Operations | (514.02M) | (747.06M) | 12.20B | 8.36B | (3.47B) | [{"date":"2019-12-31","value":-4.21,"profit":false},{"date":"2020-12-31","value":-6.12,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":68.53,"profit":true},{"date":"2023-12-31","value":-28.41,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (514.02M) | (747.06M) | 12.20B | 8.36B | (4.71B) | [{"date":"2019-12-31","value":-4.21,"profit":false},{"date":"2020-12-31","value":-6.12,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":68.53,"profit":true},{"date":"2023-12-31","value":-38.63,"profit":false}] |
EPS (Diluted) | (1.55) | (1.94) | 28.29 | 19.96 | (12.41) | [{"date":"2019-12-31","value":-5.48,"profit":false},{"date":"2020-12-31","value":-6.86,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":70.55,"profit":true},{"date":"2023-12-31","value":-43.87,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MRNA | |
---|---|
Cash Ratio | 0.75 |
Current Ratio | 4.39 |
Quick Ratio | 4.20 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MRNA | |
---|---|
ROA (LTM) | -9.55% |
ROE (LTM) | -17.52% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MRNA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.25 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MRNA | |
---|---|
Trailing PE | NM |
Forward PE | 32.47 |
P/S (TTM) | 3.09 |
P/B | 1.35 |
Price/FCF | NM |
EV/R | 2.09 |
EV/Ebitda | 4.64 |
PEG | NM |
Moderna Inc (MRNA) share price today is $39.304
Yes, Indians can buy shares of Moderna Inc (MRNA) on Vested. To buy Moderna Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MRNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Moderna Inc (MRNA) via the Vested app. You can start investing in Moderna Inc (MRNA) with a minimum investment of $1.
You can invest in shares of Moderna Inc (MRNA) via Vested in three simple steps:
The 52-week high price of Moderna Inc (MRNA) is $170.47. The 52-week low price of Moderna Inc (MRNA) is $35.8.
The price-to-earnings (P/E) ratio of Moderna Inc (MRNA) is
The price-to-book (P/B) ratio of Moderna Inc (MRNA) is 1.35
The dividend yield of Moderna Inc (MRNA) is 0.00%
The market capitalization of Moderna Inc (MRNA) is $15.69B
The stock symbol (or ticker) of Moderna Inc is MRNA